128640-73-3

Upstream product

• 14527-26-5 2-methylisothiourea sulphate 
• 105-56-6 ethyl 2-cyanoacetate 
• 591-31-1 3-methoxy-benzaldehyde 
• 867-44-7 S-Methylisothiourea sulfate 
• 131890-31-8 6-(3-methoxyphenyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile 
• 74-88-4 methyl iodide 

Downstream Products

• 131890-48-7 2-anilino-5-cyano-6-(3-methoxyphenyl)-3,4-dihydropyrimidin-4-one 
• 131890-42-1 5-cyano-6-(3-methoxyphenyl)-3-methyl-2-methylthio-3,4-dihydropyrimidin-4-one 
• 128666-82-0 5-carbonitrile-4-chloro-6-(3-methoxyphenyl)-2-(methylthio)pyrimidine 
• 405891-28-3 5-cyano-4-(3-methoxyphenyl)-2-methylthio-6-vinyl-pyrimidine 
• 945001-45-6 C₁₇H₁₇N₅O₂S 
• 131890-59-0 5-Amino-1-[5-cyano-4-(3-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-2-yl]-1H-pyrazole-4-carboxylic acid ethyl ester 
• 131890-58-9 2-(5-amino-4-ethoxycarbonylpyrazol-1-yl)-5-cyano-6-(3-methoxyphenyl)-3,4-dihydropyrimidin-4-one 
• 131890-61-4 2-(5-amino-4-cyano-3-methylthiopyrazol-1-yl)-5-cyano-6-(3-methoxyphenyl)-3,4-dihydropyrimidin-4-one 
• 131890-70-5 5-cyano-3-methyl-6-(3-methoxyphenyl)-2-piperonalhydrazino-3,4-dihydropyrimidin-4-one 
• 131890-62-5 2-(5-Amino-4-cyano-3-methylsulfanyl-pyrazol-1-yl)-1-methyl-6-oxo-4-p-tolyl-1,6-dihydro-pyrimidine-5-carbonitrile 
• 131890-51-2 5-cyano-2-N-phenylpiperazino-6-(3-methoxyphenyl)-3-methyl-3,4-dihydropyrimidin-4-one 
• 131890-72-7 6-cyano-5-(3-methoxyphenyl)-8-methyltetrazolo<1,5-a>pyrimidin-7-one 
• 131890-66-9 6-cyano-5-(3-methoxyphenyl)-8-methyl-1,2,4-triazolo<3,4-b>pyrimidin-7-one 
• 131890-52-3 5-cyano-2-hydrazino-6-(3-methoxyphenyl)-3-methyl-3,4-dihydropyrimidin-4-one 

Relevant academic research and scientific papers

Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors

The serine/threonine specific protein kinase B-Raf is part of the MAPK pathway and is an interesting oncology target. We have identified thieno[2,3-d]pyrimidines as a core scaffold of small molecule B-Raf inhibitors. The SAR of analogs in this series will be described.

Bicyclic heteroaromatic compounds

A bicyclic heteroaromatic compound according to general formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 is (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl; all optionally substituted with one or

Bicyclic heteroamatic compounds useful as LH agonists

The invention relates to a bicyclic heteroaromatic derivative compound according to general formula (I), or a pharmaceutically acceptable salt thereof, wherein R1is NR5R6, OR5, SR5or R7; R5and R6are independently selected from H, (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, alkyl(1-8C)carbonyl, (6-14C)arylcarbonyl, (6-14C)aryl or (4-13C)heteroaryl, or R5and R6together are joined in a (2-7C)heterocloalkyl ring; R7is (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl, R2is (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, or (6-14C)aryl or (4-13C)heteroaryl, both optionally substituted with one or more substituents selected from (1-8C)alkyl, (1-8C)alkylthio, (1-8C)(di)alkylamino, (1-8C)alkoxy, (2-8C)alkenyl, or (2-8C)alkynyl; R3is (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, or (6-14C)aryl or (4-13C)heteroaryl, both optionally substituted with one or more substituents selected from (1-8C)alkyl, (1-8C)(di)alkylamino or (1-8C)alkoxy; X is S, O or N(R4); R4is H, (1-8C)alkyl, (1-8C)alkylcarbonyl, (6-14C)arylcarbonyl or (6-14C)aryl(1-8C)alkyl; Y is CH or N; Z is NH2or OH; A is S, N(H), N(R9), O or a bond; R9can be selected from the same groups as described for R2and B is N(H), O or a bond. The compounds of the invention have LH receptor activating activity and can be used in fertility regulating therapies.